114 related articles for article (PubMed ID: 19189463)
1. [Obtaining of outer membrane protein I of Pseudomonas aeruginosa and assessment of its antigenic properties].
Gatypova EV; Zlygostev SA; Kaloshin AA; Mikhaĭlova NA
Zh Mikrobiol Epidemiol Immunobiol; 2008; (6):50-3. PubMed ID: 19189463
[TBL] [Abstract][Full Text] [Related]
2. [Preparation of Pseudomonas aeruginosa recombinant outer-membrane protein F and the study of its antigenic properties].
Kaloshin AA; Zlygostev SA; Toropchina IuN; Kurbatova EA; Zverev VV; Mikhaĭlova NA
Zh Mikrobiol Epidemiol Immunobiol; 2005; (5):50-3. PubMed ID: 16279535
[TBL] [Abstract][Full Text] [Related]
3. [Immunobiological properties of recombinant L peptide from the Pseudomonas aeruginosa outer membrane].
Gatypova EV; Zlygostev SA; Kaloshin AA; Mikhaĭlova NA
Vestn Ross Akad Med Nauk; 2009; (4):25-8. PubMed ID: 19514308
[TBL] [Abstract][Full Text] [Related]
4. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
[TBL] [Abstract][Full Text] [Related]
5. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
[TBL] [Abstract][Full Text] [Related]
6. [Production of hybrid protein OprF-OprL of Pseudomonas aeruginosa].
Kaloshin AA; Mikhaĭlova NA; Leonova EI
Zh Mikrobiol Epidemiol Immunobiol; 2012; (3):35-43. PubMed ID: 22830272
[TBL] [Abstract][Full Text] [Related]
7. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli.
Finke M; Duchêne M; Eckhardt A; Domdey H; von Specht BU
Infect Immun; 1990 Jul; 58(7):2241-4. PubMed ID: 2114360
[TBL] [Abstract][Full Text] [Related]
8. The Pseudomonas aeruginosa outer membrane protein I vaccine: immunogenicity and safe administration in man.
von Specht BU; Lücking HC; Blum B; Schmitt A; Hungerer KD; Domdey H
Behring Inst Mitt; 1997 Feb; (98):326-37. PubMed ID: 9382756
[TBL] [Abstract][Full Text] [Related]
9. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.
Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W
Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788
[TBL] [Abstract][Full Text] [Related]
10. [Study of immunogenic properties of recombinant outer membrane proteins F and L from Pseudomonas aeruginosa].
Kaloshin AA; Zlygostev SA; Gatypova EV; Mikhaĭlova NA
Zh Mikrobiol Epidemiol Immunobiol; 2008; (5):76-9. PubMed ID: 19004286
[TBL] [Abstract][Full Text] [Related]
11. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.
Weimer ET; Lu H; Kock ND; Wozniak DJ; Mizel SB
Infect Immun; 2009 Jun; 77(6):2356-66. PubMed ID: 19349426
[TBL] [Abstract][Full Text] [Related]
12. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies.
Finke M; Muth G; Reichhelm T; Thoma M; Duchêne M; Hungerer KD; Domdey H; von Specht BU
Infect Immun; 1991 Apr; 59(4):1251-4. PubMed ID: 1706316
[TBL] [Abstract][Full Text] [Related]
13. A hybrid outer membrane protein antigen for vaccination against Pseudomonas aeruginosa.
Gabelsberger J; Knapp B; Bauersachs S; Enz UI; von Specht BU; Domdey H
Behring Inst Mitt; 1997 Feb; (98):302-14. PubMed ID: 9382754
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of properties of Pseudomonas aeruginosa recombinant outer membrane protein F (OprF)].
Zlygostev SA; Gataullin AG; Kaloshin AA; Mikhaĭlova NA; Zverev VV
Zh Mikrobiol Epidemiol Immunobiol; 2006; (7):43-7. PubMed ID: 17297879
[TBL] [Abstract][Full Text] [Related]
15. Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins.
von Specht BU; Knapp B; Muth G; Bröker M; Hungerer KD; Diehl KD; Massarrat K; Seemann A; Domdey H
Infect Immun; 1995 May; 63(5):1855-62. PubMed ID: 7729895
[TBL] [Abstract][Full Text] [Related]
16. Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A.
Gartner T; Baeten M; Otieno S; Revets H; De Baetselier P; Huygen K
Immunol Lett; 2007 Jul; 111(1):26-35. PubMed ID: 17570535
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of gram-negative bacteria for Pseudomonas aeruginosa lipoprotein I using a monoclonal antibody.
Sciortino CV
Hybridoma; 1993 Jun; 12(3):327-32. PubMed ID: 7689535
[TBL] [Abstract][Full Text] [Related]
18. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
[TBL] [Abstract][Full Text] [Related]
19. Studies on phagocytosis of mucoid and nonmucoid variants of Pseudomonas aeruginosa. III. Polyvalent serum against three mucoid immunotypes potentiates phagocytosis of all (7) mucoid immunotypes.
Gościniak G; Grzybek-Hryncewicz K
Arch Immunol Ther Exp (Warsz); 1988; 36(2):195-203. PubMed ID: 3149178
[TBL] [Abstract][Full Text] [Related]
20. [Antigenic properties of Pseudomonas aeruginosa anatoxin and the protective action of antitoxic anti-Pseudomonas aeruginosa serum].
Podgornaia LG; Dziuban NF
Zh Mikrobiol Epidemiol Immunobiol; 1986 Jun; (6):67-9. PubMed ID: 3092510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
